Background The nucleos (t) ide analogues (NAs) entecavir (ETV), tenofovir disoproxil
fumarate (TDF) and tenofovir alafenamide (TAF) are preferred treatment options for patients …

Background & Aims There have been conflicting results from studies comparing the risk of
hepatocellular carcinoma (HCC) in patients with chronic hepatitis B virus (HBV) infection …

Nucleos (t) ide analogues with high barrier to resistance are regarded as the principal
therapeutic option for chronic hepatitis B (CHB). Treatment with entecavir (ETV), tenofovir …

Background For most adults with HIV-1 and hepatitis B virus (HBV) coinfection, initial
recommended treatment is a tenofovir-containing antiretroviral regimen, but no randomised …

Abstract Background & Aims Tenofovir disoproxil fumarate (TDF) is a first‐line treatment for
chronic hepatitis B (CHB). We aimed to describe the efficacy and safety profiles of TDF …

Objective The use of tenofovir (TDF) and entecavir (ETV) in patients with chronic hepatitis B
(CHB) has led to a decrease in the incidence of hepatocellular carcinoma (HCC) and liver …

METHODS: This was a territory-wide observational cohort study in Hong Kong. We identified
patients through electronic medical records based on the prescriptions of immune …

Patients with chronic hepatitis B (CHB) are aging because of improved survival under better
health care. This has an important implication on the choice of antiviral treatment (AVT) …

Background and Aims Real‐world data for treatment effectiveness and renal outcomes in
chronic hepatitis B (CHB) patients who were switched to the new and safer prodrug tenofovir …

Background & Aims Systemic corticosteroids may cause HBV reactivation, but the impact on
patients with previous HBV exposure is poorly defined. We aimed to study the risk of HBsAg …